• Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given a price target of $100 by Guggenheim, suggesting a substantial growth potential from its current trading price.
• The company announced a proposed underwritten public offering valued at $150 million, indicating confidence in its future prospects and a strategy to fuel further development.
• With a current stock price of $31.80 and a year-high of $32.80, DNTH showcases volatility but also a significant interest from investors, as evidenced by a trading volume of 5.94 million shares.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company specializing in advanced antibody complement therapeutics for severe autoimmune diseases, has recently been in the spotlight. On September 8, 2025, Yatin Suneja from Guggenheim set a price target of $100 for DNTH. At that time, the stock was trading at $31.73, indicating a potential for significant growth.

Recently, DNTH announced a proposed underwritten public offering valued at $150 million. This offering includes shares of its common stock or pre-funded warrants for certain investors. Additionally, Dianthus plans to provide underwriters with a 30-day option to purchase up to an extra $22.5 million in shares. The completion of this offering depends on market conditions and other factors.

The stock for DNTH is currently priced at $31.80, showing a 20% increase with a change of $5.30. Today, the stock has fluctuated between a low of $25 and a high of $32.80, which is also its highest price over the past year. The lowest price for the year was $13.37, highlighting the stock's volatility.

DNTH has a market capitalization of approximately $1.02 billion, reflecting its size in the biotechnology sector. Today's trading volume has reached 5.94 million shares, indicating strong investor interest. The proposed public offering and recent price target suggest potential growth opportunities for the company.